The volume of safety data generated across a modern pharmacovigilance system has outgrown what manual review alone can keep pace with. Spontaneous reports, literature, social listening, clinical data and patient-support programs all feed the safety database. Artificial intelligence offers a way to screen that volume far faster — but only a disciplined, GVP-aligned process preserves the human judgment regulators expect. This article looks at how to adopt AI in signal detection responsibly.
What AI does well in signal detection
Signal detection is, at its core, a screening problem: finding the small number of meaningful patterns hidden in a large, noisy dataset. That is precisely where machine learning excels.
Used well, AI-assisted methods can:
- Triage large datasets quickly, prioritizing the cases and patterns most likely to represent a genuine signal.
- Surface non-obvious associations across data sources that traditional disproportionality methods might miss.
- Reduce manual screening burden, freeing qualified safety scientists to spend their time on validation and assessment rather than first-pass review.
- Improve consistency, applying the same screening logic uniformly across very large volumes.
The goal is not to replace the safety physician or scientist. It is to get the right cases in front of them faster.
Where human judgment remains essential
Signal detection can be accelerated by AI. Signal validation and assessment cannot be delegated to it. Deciding whether a statistical association reflects a true causal safety concern requires clinical reasoning, knowledge of the product and disease, and benefit-risk judgment — all of which remain human responsibilities under EU GVP Module IX.
This is the critical design principle: AI assists screening; qualified people make decisions. A signal-management process that lets an algorithm close potential signals without documented human review is not defensible.
Keeping the process inspection-ready
Adopting AI does not change what regulators expect to see; it raises the bar on documentation. An inspection-ready, AI-assisted signal-management process needs:
- A documented methodology describing how the AI tool is used, what it screens, and where human review intervenes.
- Validation of the tool for its intended use, consistent with computerized-system and data-integrity expectations.
- A signal-tracking record that captures detection, validation, assessment and outcome — regardless of whether detection was statistical, AI-assisted or manual.
- Clear human accountability at the validation and assessment steps, with rationale recorded.
In other words, AI is held to the same standards as any other system in a GxP environment: validated, controlled, documented and overseen.
Data quality is the foundation
AI amplifies whatever is in your data — including its flaws. Inconsistent coding, duplicate cases and incomplete narratives degrade model performance just as they degrade manual review. Investment in MedDRA coding consistency, robust de-duplication and high-quality case processing pays off twice: once in routine compliance, and again in the reliability of any AI layered on top.
A pragmatic adoption path
Organizations that adopt AI successfully tend to do so incrementally:
- Start with AI-assisted triage of existing detection outputs, keeping established methods running in parallel.
- Compare and calibrate the AI's prioritization against expert judgment before relying on it.
- Document everything — methodology, validation, and the human-review checkpoints — from day one.
- Train the safety team so reviewers understand the tool's strengths and limits.
The takeaway
AI is a genuine advance for pharmacovigilance signal detection — but it is a tool for screening, not for deciding. The organizations that benefit most are those that pair modern methods with disciplined GVP governance: validated tools, documented methodology, high-quality data and clear human accountability for every safety decision.
PharmExpert designs and audits pharmacovigilance systems, including AI-assisted signal management aligned to EU GVP. Talk to our PV team about adopting it responsibly.